QUOTED. 9 June 2021. CVRx.
CVRx, which markets the implantable baroreflex activation stimulation technology Barostim Neo, plans to raise $75m in an IPO. See what the company said about it here.
“Our mission is to capitalize upon our first-mover advantage to become the global leader in providing clinically proven, innovative, and minimally invasive neuromodulation solutions that improve the health of patients with HFrEF and other cardiovascular diseases.” – CVRx
Click here for a free trial of Medtech Insight